Curaleaf completed the acquisition of a 55% stake in Four 20 Pharma.

Curaleaf, a provider of consumer products in cannabis, completed the acquisition of a 55% stake in Four 20 Pharma, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis. Financial terms were not disclosed. "Four 20 Pharma is a leading German distributor with a branded product that consumers love. They've captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering. As such, Four 20 Pharma is uniquely positioned to capitalize on Germany's conversion from a medical to an adult use market and we're thrilled to be partnering with their talented management team," Miles Worne, Curaleaf President.